

Nicola Fossati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5657996/publications.pdf>

Version: 2024-02-01

213
papers

12,185
citations

43973

48
h-index

30848

102
g-index

215
all docs

215
docs citations

215
times ranked

10043
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2017, 71, 618-629.	0.9	2,497
2	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	0.9	1,545
3	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	0.9	633
4	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 84-109.	0.9	348
5	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. <i>European Urology</i> , 2017, 72, 250-266.	0.9	305
6	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 75, 967-987.	0.9	278
7	Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3939-3947.	0.8	246
8	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , 2020, 77, 439-446.	0.9	228
9	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. <i>European Urology</i> , 2019, 75, 506-514.	0.9	188
10	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 869-885.	0.9	182
11	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. <i>European Urology</i> , 2017, 72, 632-640.	0.9	165
12	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	0.9	151
13	Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study. <i>European Urology</i> , 2015, 67, 3-6.	0.9	136
14	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020, 6, 231-234.	1.6	131
15	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 701-710.	0.9	128
16	Long-Term Followup and Deterioration Rate of Anterior Substitution Urethroplasty. <i>Journal of Urology</i> , 2014, 192, 808-813.	0.2	114
17	Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>European Urology</i> , 2013, 63, 998-1008.	0.9	107
18	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. <i>European Urology</i> , 2018, 74, 357-368.	0.9	105

#	ARTICLE	IF	CITATIONS
19	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 728-733.	0.9	102
20	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. <i>European Urology</i> , 2019, 75, 176-183.	0.9	101
21	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627.	0.9	101
22	Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. <i>European Urology</i> , 2018, 73, 890-896.	0.9	87
23	Predicting Survival of Patients with Node-positive Prostate Cancer Following Multimodal Treatment. <i>European Urology</i> , 2014, 65, 554-562.	0.9	86
24	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2020, 77, 733-741.	0.9	85
25	Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 697-713.	2.6	84
26	Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. <i>European Urology</i> , 2017, 72, 289-292.	0.9	81
27	PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 192-196.	1.6	81
28	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. <i>European Urology</i> , 2017, 71, 886-893.	0.9	77
29	Robotic Assisted Simple Prostatectomy versus Holmium Laser Enucleation of the Prostate for Lower Urinary Tract Symptoms in Patients with Large Volume Prostate: A Comparative Analysis from a High Volume Center. <i>Journal of Urology</i> , 2017, 197, 1108-1114.	0.2	77
30	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020, 77, 636-643.	0.9	75
31	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	0.9	74
32	Multicenter European External Validation of a Prostate Health Index-based Nomogram for Predicting Prostate Cancer at Extended Biopsy. <i>European Urology</i> , 2014, 66, 906-912.	0.9	73
33	Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer. <i>European Urology</i> , 2017, 71, 249-256.	0.9	73
34	Ventral Oral Mucosal Onlay Graft Urethroplasty in Nontraumatic Bulbar Urethral Strictures: Surgical Technique and Multivariable Analysis of Results in 214 Patients. <i>European Urology</i> , 2013, 64, 440-447.	0.9	70
35	Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. <i>European Urology</i> , 2015, 68, 132-138.	0.9	67
36	The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study. <i>Journal of Urology</i> , 2019, 202, 108-113.	0.2	67

#	ARTICLE	IF	CITATIONS
37	Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. <i>European Urology</i> , 2017, 71, 945-951.	0.9	63
38	The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. <i>European Urology</i> , 2016, 69, 1142-1148.	0.9	60
39	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 436-444.	0.9	60
40	Prediction of Early and Late Complications after Oral Mucosal Graft Harvesting: Multivariable Analysis from a Cohort of 553 Consecutive Patients. <i>Journal of Urology</i> , 2014, 191, 688-693.	0.2	57
41	Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. <i>Journal of Urology</i> , 2016, 196, 1008-1013.	0.2	57
42	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). <i>European Urology Oncology</i> , 2021, 4, 971-979.	2.6	56
43	Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 669-675.	0.2	55
44	Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 120-128.	2.6	55
45	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. <i>European Urology</i> , 2020, 77, 576-580.	0.9	55
46	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2020, 78, 138-142.	0.9	55
47	Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. <i>European Urology Oncology</i> , 2018, 1, 46-53.	2.6	53
48	Prediction of Complications Following Partial Nephrectomy: Implications for Ablative Techniques Candidates. <i>European Urology</i> , 2016, 69, 676-682.	0.9	52
49	Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e793-e800.	0.9	51
50	The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. <i>European Urology</i> , 2018, 74, 4-7.	0.9	50
51	The Surgical Learning Curve for One-stage Anterior Urethroplasty: A Prospective Single-surgeon Study. <i>European Urology</i> , 2016, 69, 686-690.	0.9	49
52	Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. <i>European Urology</i> , 2017, 72, 432-438.	0.9	49
53	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49
54	Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival. <i>European Urology</i> , 2015, 68, 777-784.	0.9	48

#	ARTICLE	IF	CITATIONS
55	Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 22.e1-22.e9.	0.8	44
56	Margin, Ischemia, and Complications System to Report Perioperative Outcomes of Robotic Partial Nephrectomy: A European Multicenter Observational Study (EMOS Project). <i>Urology</i> , 2015, 85, 589-595.	0.5	43
57	Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons. <i>Journal of Endourology</i> , 2017, 31, 872-877.	1.1	43
58	Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 29-36.	2.6	43
59	Robot-assisted, Single-site, Dismembered Pyeloplasty for Ureteropelvic Junction Obstruction with the New da Vinci Platform: A Stage 2a Study. <i>European Urology</i> , 2015, 67, 151-156.	0.9	41
60	Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 150.e9-150.e15.	0.8	40
61	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>Prostate</i> , 2018, 78, 469-475.	1.2	40
62	There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies. <i>European Urology Oncology</i> , 2020, 3, 112-118.	2.6	40
63	Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 42-48.	2.6	40
64	When to Perform Karyotype Analysis in Infertile Men? Validation of the European Association of Urology Guidelines with the Proposal of a New Predictive Model. <i>European Urology</i> , 2016, 70, 920-923.	0.9	39
65	Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of Morbidity, Renal Function, and Oncologic Outcomes. <i>European Urology Oncology</i> , 2018, 1, 61-68.	2.6	38
66	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. <i>International Urology and Nephrology</i> , 2018, 50, 71-78.	0.6	37
67	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. <i>European Urology</i> , 2018, 73, 512-518.	0.9	36
68	Relationship of Chronic Histologic Prostatic Inflammation in Biopsy Specimens With Serum Isoform [-2]proPSA (p2PSA), %p2PSA, and Prostate Health Index in Men With a Total Prostate-specific Antigen of 4-10 ng/mL and Normal Digital Rectal Examination. <i>Urology</i> , 2014, 83, 606-612.	0.5	34
69	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. <i>European Urology</i> , 2022, 81, 337-346.	0.9	33
70	Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged ≤ 60 years: results from a multicentric European study. <i>BJU International</i> , 2015, 115, 913-920.	1.3	32
71	First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. <i>BJU International</i> , 2018, 121, 592-599.	1.3	32
72	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , 2020, 204, 296-302.	0.2	32

#	ARTICLE	IF	CITATIONS
73	The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. <i>European Urology Oncology</i> , 2019, 2, 541-548.	2.6	31
74	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. <i>European Urology Oncology</i> , 2020, 3, 739-747.	2.6	31
75	Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 1-10.	2.0	30
76	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 48-53.	3.0	30
77	Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. <i>European Urology</i> , 2022, 81, 193-203.	0.9	30
78	Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians. <i>Journal of Endourology</i> , 2016, 30, 792-798.	1.1	29
79	Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 29.e21-29.e28.	0.8	28
80	Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. <i>BJU International</i> , 2016, 117, 740-747.	1.3	28
81	Survival benefit of local versus no local treatment for metastatic prostate cancer—Impact of baseline PSA and metastatic substages. <i>Prostate</i> , 2018, 78, 753-757.	1.2	27
82	How can we expand active surveillance criteria in patients with low and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. <i>BJU International</i> , 2018, 122, 823-830.	1.3	27
83	Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 376-384.e1.	0.9	27
84	Predicting survival of men with recurrent prostate cancer after radical prostatectomy. <i>European Journal of Cancer</i> , 2016, 54, 27-34.	1.3	26
85	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. <i>European Urology Oncology</i> , 2021, 4, 405-423.	2.6	26
86	Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature. <i>Korean Journal of Urology</i> , 2014, 55, 436.	1.2	25
87	Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMetheus project, a multicentre European prospective study. <i>BJU International</i> , 2015, 115, 537-545.	1.3	25
88	Comparison of renal function detriments after local tumor ablation or partial nephrectomy for renal cell carcinoma. <i>World Journal of Urology</i> , 2016, 34, 383-389.	1.2	25
89	Pelvic Lymph Node Dissection in Prostate Cancer: Indications, Extent and Tailored Approaches. <i>Urologia</i> , 2017, 84, 9-19.	0.3	25
90	Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	24

#	ARTICLE	IF	CITATIONS
91	Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer. <i>BJU International</i> , 2018, 121, 421-427.	1.3	24
92	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. <i>World Journal of Urology</i> , 2018, 36, 7-13.	1.2	23
93	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. <i>European Urology Oncology</i> , 2021, 4, 1001-1005.	2.6	23
94	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	2.6	23
95	The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study. <i>Prostate</i> , 2017, 77, 263-273.	1.2	22
96	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 573-580.	2.0	22
97	Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. <i>Prostate</i> , 2015, 75, 1484-1491.	1.2	21
98	Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 57.e1-57.e7.	0.8	21
99	Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>European Urology</i> , 2017, 72, 910-917.	0.9	21
100	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 674-689.	1.6	21
101	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 256.e7-256.e13.	0.8	20
102	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 829-833.	2.6	20
103	Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 461.e7-461.e14.	0.8	19
104	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. <i>Radiotherapy and Oncology</i> , 2013, 109, 211-216.	0.3	18
105	The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer—The Problem Is How to Avoid Finding These Cancers. <i>European Urology</i> , 2016, 70, 547-548.	0.9	18
106	The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1351-1358.	2.3	17
107	Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2016, 34, 1429-1436.	1.2	17
108	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. <i>European Urology</i> , 2019, 75, 817-825.	0.9	17

#	ARTICLE	IF	CITATIONS
109	Urethral Lift for Benign Prostatic Hyperplasia: A Comprehensive Review of the Literature. <i>Current Urology Reports</i> , 2013, 14, 620-627.	1.0	16
110	Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer. <i>International Journal of Urology</i> , 2015, 22, 555-561.	0.5	16
111	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in pT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 333-340.	0.4	16
112	Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. <i>European Urology</i> , 2016, 70, 429-435.	0.9	16
113	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 59.e15-59.e22.	0.8	16
114	Correlation Between Primary Hypospadias Repair and Subsequent Urethral Strictures in a Series of 408 Adult Patients. <i>European Urology Focus</i> , 2017, 3, 287-292.	1.6	16
115	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	0.9	16
116	Population-based assessment of cancer-specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis. <i>BJU International</i> , 2016, 118, 541-546.	1.3	15
117	Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?. <i>Journal of Sexual Medicine</i> , 2016, 13, 669-678.	0.3	15
118	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 234.e13-234.e19.	0.8	15
119	Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. <i>European Urology Focus</i> , 2018, 4, 68-74.	1.6	15
120	Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2019, 37, 1557-1570.	1.2	15
121	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	0.9	15
122	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 105-113.e2.	0.9	15
123	Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. <i>European Urology Oncology</i> , 2020, 3, 474-480.	2.6	15
124	Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy. <i>JAMA Network Open</i> , 2020, 3, e201913.	2.8	15
125	Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 67-71.	0.9	14
126	Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?. <i>European Urology</i> , 2018, 74, 131-133.	0.9	14

#	ARTICLE	IF	CITATIONS
127	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	0.9	14
128	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1497-1503.	0.8	13
129	Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis. <i>World Journal of Urology</i> , 2016, 34, 1357-1366.	1.2	13
130	Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. <i>World Journal of Urology</i> , 2017, 35, 51-56.	1.2	13
131	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , 2018, 74, 134-137.	0.9	13
132	Focus on Internal Urethrotomy as Primary Treatment for Untreated Bulbar Urethral Strictures: Results from a Multivariable Analysis. <i>European Urology Focus</i> , 2020, 6, 164-169.	1.6	13
133	Oncologic outcomes in prostate cancer patients treated with robot-assisted radical prostatectomy: results from a single institution series with more than 10 years follow up. <i>Minerva Urologica e Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 38-46.	3.9	13
134	Optimizing postoperative sexual function after radical prostatectomy. <i>Therapeutic Advances in Urology</i> , 2012, 4, 347-365.	0.9	12
135	Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 594-600.	2.6	12
136	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. <i>European Urology Focus</i> , 2019, 5, 381-388.	1.6	12
137	The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: Conditional survival analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 43.e9-43.e16.	0.8	11
138	Minimally Invasive Partial Nephrectomy Versus Laparoscopic Cryoablation for Patients Newly Diagnosed with a Single Small Renal Mass. <i>European Urology Focus</i> , 2015, 1, 66-72.	1.6	11
139	Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney Cancer. <i>Urology</i> , 2017, 102, 130-137.	0.5	11
140	Robotic and Open Radical Prostatectomy: The First Prospective Randomised Controlled Trial Fuels Debate Rather than Closing the Question. <i>European Urology</i> , 2017, 71, 307-308.	0.9	11
141	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. <i>European Urology Focus</i> , 2019, 5, 449-456.	1.6	11
142	Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions. <i>BJU International</i> , 2022, 129, 201-207.	1.3	11
143	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e341-e346.	0.9	10
144	Salvage surgery for nodal recurrent prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 604-611.	0.9	10

#	ARTICLE	IF	CITATIONS
145	Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. <i>BJU International</i> , 2017, 120, 69-75.	1.3	10
146	Technical and Functional Validation of a Teleoperated Multirobots Platform for Minimally Invasive Surgery. <i>IEEE Transactions on Medical Robotics and Bionics</i> , 2020, 2, 148-156.	2.1	10
147	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e15-235.e21.	0.8	10
148	Salvage Lymph Node Dissection for Node-only Recurrence of Prostate Cancer: Ready for Prime Time?. <i>European Urology</i> , 2017, 71, 693-694.	0.9	9
149	New surgical approaches for clinically high-risk or metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1013-1031.	1.1	9
150	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. <i>World Journal of Urology</i> , 2022, 40, 103-110.	1.2	9
151	Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 739-755.	1.1	8
152	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019, 75, 699-702.	0.9	8
153	Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 204-209.	0.8	8
154	Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. <i>European Urology Oncology</i> , 2022, 5, 587-600.	2.6	8
155	Risk calculator for prediction of treatment-related urethroplasty failure in patients with penile urethral strictures. <i>International Urology and Nephrology</i> , 2020, 52, 1079-1085.	0.6	8
156	The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer. <i>Current Oncology Reports</i> , 2015, 17, 53.	1.8	7
157	Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e177-e182.	0.9	7
158	Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond. <i>European Urology Focus</i> , 2021, 7, 245-249.	1.6	7
159	Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 784.e1-784.e9.	0.8	7
160	Rationale for local treatment in the management of metastatic prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 266-272.	0.5	6
161	Magnetic Resonance Imaging for Membranous Urethral Length Assessment Prior to Radical Prostatectomy: Can it Really Improve Prostate Cancer Management?. <i>European Urology</i> , 2017, 71, 379-380.	0.9	6
162	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 239.e9-239.e15.	0.8	6

#	ARTICLE	IF	CITATIONS
163	An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer. <i>Urology Case Reports</i> , 2017, 12, 34-36.	0.1	5
164	When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging. <i>Urology</i> , 2017, 110, 114-120.	0.5	5
165	Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. <i>European Urology Focus</i> , 2019, 5, 545-549.	1.6	5
166	Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. <i>Minerva Urology and Nephrology</i> , 2021, 73, 481-488.	1.3	5
167	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. <i>BJU International</i> , 2015, 116, 366-372.	1.3	4
168	Re: Editorial Comment on Clinical Performance of Serum Isoform -2 proPSA (p2PSA) and its Derivatives, Namely %p2PSA and PHI (Prostate Health Index) in Men Younger than 60 Years of Age: Results from a Multicentric European Study. <i>Journal of Urology</i> , 2015, 194, 265-266.	0.2	4
169	Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How?. <i>Journal of Clinical Oncology</i> , 2017, 35, 469-470.	0.8	4
170	Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine. <i>Prostate</i> , 2017, 77, 234-241.	1.2	4
171	Anastomotic leaks and catheter time after salvage robot-assisted radical prostatectomy. <i>Translational Andrology and Urology</i> , 2018, 7, S141-S143.	0.6	4
172	The emerging role of PET-CT scan after radical prostatectomy: still a long way to go. <i>Lancet Oncology</i> , The, 2019, 20, 1193-1195.	5.1	4
173	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2021, 7, 1092-1099.	1.6	4
174	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. <i>European Urology Oncology</i> , 2022, 5, 285-295.	2.6	4
175	Re: Systematic Review and Meta-Analysis of Perioperative and Oncologic Outcomes of Laparoscopic Cryoablation versus Laparoscopic Partial Nephrectomy for the Treatment of Small Renal Tumors. <i>Journal of Urology</i> , 2014, 192, 1887-1888.	0.2	3
176	STAMPEDE trial and patients with non-metastatic prostate cancer. <i>Lancet</i> , The, 2016, 388, 234-235.	6.3	3
177	Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1137-1142.	2.0	3
178	Does Radiotherapy Plus Androgen-Deprivation Therapy Represent the Best Treatment Approach in Elderly Patients With Locally Advanced Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2831-2832.	0.8	2
179	Timing of androgen-deprivation therapy for prostate cancer: still a long way to go. <i>Lancet Oncology</i> , The, 2016, 17, e313.	5.1	2
180	Reply to Pascal Mouracade's Letter to the Editor re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. <i>Eur Urol</i> 2017;72:289-92. Do the Data Violate Kaplan-Meier Assumptions?. <i>European Urology</i> , 2017, 72, e31.	0.9	2

#	ARTICLE	IF	CITATIONS
181	Requiem for Open Radical Cystectomy in Bladder Cancer Patients. <i>European Urology Oncology</i> , 2019, 2, 196-197.	2.6	2
182	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 301-304.	2.6	2
183	Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance. <i>BJU International</i> , 2013, 112, E234-42.	1.3	1
184	MP87-13 IMPACT OF PRE-TREATMENT PSA LEVEL ON CANCER CONTROL AFTER EARLY SALVAGE RADIATION THERAPY POST RADICAL PROSTATECTOMY: NEED FOR PATIENT STRATIFICATION ACCORDING TO PROSTATE CANCER FEATURES. <i>Journal of Urology</i> , 2015, 193, .	0.2	1
185	RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	1
186	Reply to C.G. Rusthoven et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1989-1989.	0.8	1
187	Re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. <i>Eur Urol</i> 2016;70:588â€“96. <i>European Urology</i> , 2016, 70, e108-e109.	0.9	1
188	Dose Escalation in Salvage Radiation Therapy and Urinary Toxicity: A Small Price to Pay for a Significant Prospective Benefit. <i>Journal of Clinical Oncology</i> , 2016, 34, 1704-1705.	0.8	1
189	Reply to Marc A. Bjurlin, Lee C. Zhao, and Michael D. Stifelman's Letter to the Editor Re: NicolÃ² Maria Buffi, Giovanni Lughezzani, Rodolfo Hurlle, et al. Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2016.07.022 . <i>European Urology</i> , 2017, 71, e92-e93.	0.9	1
190	Re: Vasilis Stavrinos, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443â€“51. <i>European Urology</i> , 2020, 78, e165.	0.9	1
191	Metastatic hormone-sensitive prostate cancer: local treatment strategies. <i>World Journal of Urology</i> , 2022, 40, 881-882.	1.2	1
192	Re: Marra et al. Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases. <i>BJU International</i> , 2021, 128, 523-523.	1.3	1
193	Re: The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies. <i>Journal of Urology</i> , 2020, 204, 843-843.	0.2	1
194	Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy. <i>Journal of Urology</i> , 2022, 208, 1046-1055.	0.2	1
195	The Authors Respond. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 117.2-122.	2.3	0
196	Reply from Authors re: Matthew C. Hayes, David J. Breen. Excision Versus Ablation in Renal Cancer: Optimising Outcome and Minimising Risk. <i>Eur Urol</i> 2016;69:683â€“4. <i>European Urology</i> , 2016, 69, 684-685.	0.9	0
197	Salvage radiotherapy for patients with rising PSA. <i>Lancet Oncology</i> , The, 2016, 17, e314-e315.	5.1	0
198	The Rapidly Evolving Role of Imaging in Urology: How to Balance Breakthroughs in Knowledge with Overuse. <i>European Urology Focus</i> , 2016, 2, 111-112.	1.6	0

#	ARTICLE	IF	CITATIONS
199	How can we optimize the use of prostate cancer registries?. <i>Future Oncology</i> , 2016, 12, 1093-1095.	1.1	0
200	Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?. <i>BJU International</i> , 2017, 119, 652-653.	1.3	0
201	Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 659.e7-659.e12.	0.8	0
202	Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>Eur Urol</i> 2017;72:910â€“7. <i>European Urology</i> , 2018, 73, e131-e132.	0.9	0
203	Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>Eur Urol</i> 2017;72:910â€“7. <i>European Urology</i> , 2018, 73, e36-e37.	0.9	0
204	Reply to Riccardo Bertolo's Letter to the Editor re: Giorgio Gandaglia, Carlo Andrea Bravi, Paolo Dellâ€™Oglio, et al. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. <i>Eur Urol</i> 2018;74:4â€“7. <i>European Urology</i> , 2018, 74, e116-e117.	0.9	0
205	Re: AurÃ©lie De Bruycker, Elise De Bleser, Karel Decaestecker, et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. <i>Eur Urol</i> 2019;75:826â€“33. <i>European Urology</i> , 2020, 77, e137.	0.9	0
206	Re: Ola Bratt, Erik Holmberg, Ove AndrÃ©n, et al. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). <i>Eur Urol</i> 2019;76:461â€“6. <i>European Urology</i> , 2020, 77, e136.	0.9	0
207	Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. <i>Eur Urol</i> 2019;76:106â€“14. <i>European Urology</i> , 2020, 77, e107.	0.9	0
208	Re: Histological comparison between predictive value of preoperative 3â€“T multiparametric MRI and 68 Gaâ€“PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. <i>BJU International</i> , 2021, 127, 746-746.	1.3	0
209	Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Journal of Urology</i> , 2021, 205, 340-341.	0.2	0
210	Re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. <i>Eur Urol</i> 2021;79:537â€“44. <i>European Urology</i> , 2021, 79, e132-e133.	0.9	0
211	Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Letter.. <i>Journal of Urology</i> , 2021, 205, 1839-1839.	0.2	0
212	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 302-302.	0.2	0
213	Re: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 587-587.	0.2	0